In early 2026, the "Synergy" between AAV (for long-term DNA delivery) and mRNA (for short-term protein bursts) is creating a "Hybrid Treatment Model." For complex diseases like "Heart Failure," an AAV vector is used in early 2026 to provide a permanent "Structural Repair" gene, while a follow-up mRNA dose is given to trigger "Immediate Muscle Regeneration." In early 2026, this "Dual-Modality"...
จองคิวบริการ
NR tours
Youplay
NR shop
NR jobs
facebook th
thai
English
French
Spanish
Portuguese
Italiano
Portuguese (Brazil)
china